Edgen Stock·Sep 16 2025, 22:25戻る
戻る
Coya Therapeutics Secures FDA IND Clearance for ALS Treatment, Bolstering Pipeline and Financial Position
Edgen Stock·Sep 16 2025, 22:25
[1] PRISM MarketView Features Exclusive Q&A with Coya Therapeutics CEO Arun Swaminathan on Targeting Neurodegenerative Diseases Through Treg Therapies[2] Coya Therapeutics and the FDA IND Acceptance: A Pivotal Step in the Race for ALS Treatment Innovation - AInvest[3] Dr Reddy's Share Price Surges on Partner with Alvotech to Co-Develop Biosimilar to Keytruda - Angel One